Clinical Trials: Skin Cancer
Therapeutic Area: Melanoma
Principal Investigator: Dr. Susan Tannenbaum
Title: S0008 Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma.
Description: This study is designed to evaluate whether the combination of three cycles of chemotherapy and biological therapy (IL-2 and Intron A), is more effective than
interferon given for one year in preventing a recurrence of melanoma after complete surgical removal of the primary lesion or involved lymph nodes.
Length/Duration: Up to 12 months of treatment and 10 years of follow-up
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify, contact: Diane Noel, R.N., at 860-679-3174 or dnoel@uchc.edu.
IRB #: 01-175
Sponsor: Eastern Oncology Cooperative Group (ECOG)
Therapeutic Area: Melanoma
Principal Investigator: Dr. Susan Tannenbaum
Title: E1697, Phase III Randomized Study of Four Weeks High Dose IFN a-2b in Stage T3 - T4 or N1 (microscopic) Melanoma
Description: This is a study for people with early melanoma, which can be removed surgically. The study includes a drug called Interferon Alfa-2b (IFN a-2b), which is a
substance normally produced by the body's immune system. IFN a-2b has been shown to have anti-tumor activity in advanced melanoma. Participants would be randomized to receive either IFB a-2b, or no treatment following surgical removal of the melanoma. The purpose of this study is to see if treatment with Interferon is more effective than no treatment after
surgery, in preventing melanoma from returning.
Length/Duration: 4 weeks of treatment, patients will be followed until progression or death
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify, contact: Diane Noel, R.N., at 860-679-3174 or dnoel@uchc.edu.
IRB #: 99-178
Sponsor: Eastern Oncology Cooperative Group (ECOG) |
Research
done today will be the standard treatments of tomorrow.